- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Terrill Jordan Discusses the Impact of Consolidation on Community Oncology Practices
With all the consolidation that’s taking place, practices are still trying to grow, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
With all the consolidation that’s taking place, practices are still trying to grow, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
With a high prevalence of hospital consolidation, do practices have challenges with trying to grow and diversify?
With all the consolidation that’s taking place, practices are still trying to grow. I think they face the same things they’ve always faced. I don’t know that consolidation necessarily limited their ability to grow—I think in fact some of the consolidation that takes place is amongst larger practices. So, in fact, it’s probably allowed for more growth. I think in terms of a smaller practice trying to grow, I think what they need to look to is the same things they’ve always looked to. In fact, what we’re seeing is that some hospitals are having practices leave the hospital and so there’s some growth there.
I think the demographics of the country also just naturally support growth. So, we’re going to see larger growth simply because more persons are going on Medicare, the population is aging, and so forth.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
